164 related articles for article (PubMed ID: 35565471)
1. Azacitidine vs. Decitabine in Unfit Newly Diagnosed Acute Myeloid Leukemia Patients: Results from the PETHEMA Registry.
Labrador J; Martínez-Cuadrón D; de la Fuente A; Rodríguez-Veiga R; Serrano J; Tormo M; Rodriguez-Arboli E; Ramos F; Bernal T; López-Pavía M; Trigo F; Martínez-Sánchez MP; Rodríguez-Gutiérrez JI; Rodríguez-Medina C; Gil C; Belmonte DG; Vives S; Foncillas MÁ; Pérez-Encinas M; Novo A; Recio I; Rodríguez-Macías G; Bergua JM; Noriega V; Lavilla E; Roldán-Pérez A; Sanz MA; Montesinos P; On Behalf Of Pethema Group
Cancers (Basel); 2022 May; 14(9):. PubMed ID: 35565471
[TBL] [Abstract][Full Text] [Related]
2. Predictive factors for response and survival in elderly acute myeloid leukemia patients treated with hypomethylating agents: a real-life experience.
Pepe S; Scalzulli E; Colafigli G; Di Prima A; Diverio D; Mancini M; Latagliata R; Martelli M; Foà R; Breccia M
Ann Hematol; 2020 Oct; 99(10):2405-2416. PubMed ID: 32813071
[TBL] [Abstract][Full Text] [Related]
3. Comparison between azacitidine and decitabine as front-line therapy in elderly acute myeloid leukemia patients not eligible for intensive chemotherapy.
Maurillo L; Spagnoli A; Candoni A; Papayannidis C; Borlenghi E; Lazzarotto D; Fianchi L; Sciumè M; Zannier ME; Buccisano F; Del Principe MI; Mancini V; Breccia M; Fanin R; Todisco E; Lunghi M; Palmieri R; Fracchiolla N; Musto P; Rossi G; Venditti A
Leuk Res; 2023 Apr; 127():107040. PubMed ID: 36801702
[TBL] [Abstract][Full Text] [Related]
4. Venetoclax with azacitidine or decitabine in patients with newly diagnosed acute myeloid leukemia: Long term follow-up from a phase 1b study.
Pollyea DA; Pratz K; Letai A; Jonas BA; Wei AH; Pullarkat V; Konopleva M; Thirman MJ; Arellano M; Becker PS; Chyla B; Hong WJ; Jiang Q; Potluri J; DiNardo CD
Am J Hematol; 2021 Feb; 96(2):208-217. PubMed ID: 33119898
[TBL] [Abstract][Full Text] [Related]
5. Outcomes of Newly Diagnosed Acute Myeloid Leukemia Patients Treated With Hypomethylating Agents With or Without Venetoclax: A Propensity Score-Adjusted Cohort Study.
Mustafa Ali MK; Corley EM; Alharthy H; Kline KAF; Law JY; Lee ST; Niyongere S; Duong VH; Emadi A; Baer MR
Front Oncol; 2022; 12():858202. PubMed ID: 35433414
[TBL] [Abstract][Full Text] [Related]
6. Use of Venetoclax in Patients with Relapsed or Refractory Acute Myeloid Leukemia: The PETHEMA Registry Experience.
Labrador J; Saiz-Rodríguez M; de Miguel D; de Laiglesia A; Rodríguez-Medina C; Vidriales MB; Pérez-Encinas M; Sánchez-Sánchez MJ; Cuello R; Roldán-Pérez A; Vives S; Benzo-Callejo G; Colorado M; García-Fortes M; Sayas MJ; Olivier C; Recio I; Conde-Royo D; Bienert-García Á; Vahi M; Muñoz-García C; Seri-Merino C; Tormo M; Vall-Llovera F; Foncillas MÁ; Martínez-Cuadrón D; Sanz MÁ; Montesinos P
Cancers (Basel); 2022 Mar; 14(7):. PubMed ID: 35406512
[TBL] [Abstract][Full Text] [Related]
7. Venetoclax with decitabine versus decitabine monotherapy in elderly acute myeloid leukemia: a propensity score-matched analysis.
Kwag D; Cho BS; Bang SY; Lee JH; Min GJ; Park SS; Park S; Yoon JH; Lee SE; Eom KS; Kim YJ; Lee S; Min CK; Cho SG; Lee JW; Kim HJ
Blood Cancer J; 2022 Dec; 12(12):169. PubMed ID: 36529771
[TBL] [Abstract][Full Text] [Related]
8. Comparison of Azacitidine and Decitabine in Myelodysplastic Syndromes and Acute Myeloid Leukemia: A Network Meta-analysis.
Liu W; Zhou Z; Chen L; Wang X
Clin Lymphoma Myeloma Leuk; 2021 Jun; 21(6):e530-e544. PubMed ID: 33716056
[TBL] [Abstract][Full Text] [Related]
9. [Efficacy and safety of venetoclax combined with azacitidine versus CAG regimen combined with decitabine in elderly patients with relapsed acute myeloid leukemia].
Wang P; Zhang LW; Lu CQ; Wang TZ; Shan M; Xiao JY; Tian H; Ma X; Xu Y; Wu DP
Zhonghua Nei Ke Za Zhi; 2022 Feb; 61(2):157-163. PubMed ID: 35090250
[No Abstract] [Full Text] [Related]
10. Results of a randomized phase 3 study of oral sapacitabine in elderly patients with newly diagnosed acute myeloid leukemia (SEAMLESS).
Kantarjian HM; Begna KH; Altman JK; Goldberg SL; Sekeres MA; Strickland SA; Arellano ML; Claxton DF; Baer MR; Gautier M; Berman E; Seiter K; Solomon SR; Schiller GJ; Luger SM; Butrym A; Gaidano G; Thomas XG; Montesinos P; Rizzieri DA; Quick DP; Venugopal P; Gaur R; Maness LJ; Kadia TM; Ravandi F; Buyse ME; Chiao JH
Cancer; 2021 Dec; 127(23):4421-4431. PubMed ID: 34424530
[TBL] [Abstract][Full Text] [Related]
11. [Short-term efficacy of venetoclax combined with azacitidine in acute myeloid leukemia: a single-institution experience].
Yu WJ; Jia JS; Wang J; Tang FF; Gong LZ; Liu XH; Zhu XL; Zhao XS; Huang XJ; Jiang H
Zhonghua Xue Ye Xue Za Zhi; 2022 Feb; 43(2):134-140. PubMed ID: 35381674
[No Abstract] [Full Text] [Related]
12. Multivariate and subgroup analyses of a randomized, multinational, phase 3 trial of decitabine vs treatment choice of supportive care or cytarabine in older patients with newly diagnosed acute myeloid leukemia and poor- or intermediate-risk cytogenetics.
Mayer J; Arthur C; Delaunay J; Mazur G; Thomas XG; Wierzbowska A; Ravandi F; Berrak E; Jones M; Li Y; Kantarjian HM
BMC Cancer; 2014 Feb; 14():69. PubMed ID: 24498872
[TBL] [Abstract][Full Text] [Related]
13. Demethylating therapy increases cytotoxicity of CD44v6 CAR-T cells against acute myeloid leukemia.
Tang L; Kong Y; Wang H; Zou P; Sun T; Liu Y; Zhang J; Jin N; Mao H; Zhu X; Wang J; Meng F; You Y
Front Immunol; 2023; 14():1145441. PubMed ID: 37180104
[TBL] [Abstract][Full Text] [Related]
14. Clinical Outcomes in Patients With Refractory Anemia With Excess Blasts (RAEB) Who Receive Hypomethylating Agents (HMAs).
Zeidan AM; Mearns ES; Ng CD; Shah A; Lamarre N; Yellow-Duke A; Alrawashdh N; Yang B; Cheng WH; Bui CN; Svensson A
Clin Lymphoma Myeloma Leuk; 2024 Mar; 24(3):177-186. PubMed ID: 37996264
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and toxicity of Decitabine in patients with acute myeloid leukemia (AML): A multicenter real-world experience.
Filì C; Candoni A; Zannier ME; Olivieri J; Imbergamo S; Caizzi M; Nadali G; Di Bona E; Ermacora A; Gottardi M; Facchinelli D; Ciancia R; Lazzarotto D; Dubbini MV; Festini G; Gherlinzoni F; Michieli MG; Semenzato G; Fanin R
Leuk Res; 2019 Jan; 76():33-38. PubMed ID: 30529681
[TBL] [Abstract][Full Text] [Related]
16. Comparison Between Decitabine and Azacitidine for Patients With Acute Myeloid Leukemia and Higher-Risk Myelodysplastic Syndrome: A Systematic Review and Network Meta-Analysis.
Ma J; Ge Z
Front Pharmacol; 2021; 12():701690. PubMed ID: 34483903
[No Abstract] [Full Text] [Related]
17. Comparison of 7-day azacitidine and 5-day decitabine for treating myelodysplastic syndrome.
Lee JH; Choi Y; Kim SD; Kim DY; Lee JH; Lee KH; Lee SM; Cho SH; Lee WS; Joo YD
Ann Hematol; 2013 Jul; 92(7):889-97. PubMed ID: 23420388
[TBL] [Abstract][Full Text] [Related]
18. Overall survival of glasdegib in combination with low-dose cytarabine, azacitidine, and decitabine among adult patients with previously untreated AML: comparative effectiveness using simulated treatment comparisons.
Tremblay G; Westley T; Cappelleri JC; Arondekar B; Chan G; Bell TJ; Briggs A
Clinicoecon Outcomes Res; 2019; 11():551-565. PubMed ID: 31564931
[TBL] [Abstract][Full Text] [Related]
19. Azacitidine for Front-Line Therapy of Patients with AML: Reproducible Efficacy Established by Direct Comparison of International Phase 3 Trial Data with Registry Data from the Austrian Azacitidine Registry of the AGMT Study Group.
Pleyer L; Döhner H; Dombret H; Seymour JF; Schuh AC; Beach CL; Swern AS; Burgstaller S; Stauder R; Girschikofsky M; Sill H; Schlick K; Thaler J; Halter B; Machherndl Spandl S; Zebisch A; Pichler A; Pfeilstöcker M; Autzinger EM; Lang A; Geissler K; Voskova D; Sperr WR; Hojas S; Rogulj IM; Andel J; Greil R
Int J Mol Sci; 2017 Feb; 18(2):. PubMed ID: 28212292
[TBL] [Abstract][Full Text] [Related]
20. A phase 3 trial of azacitidine versus a semi-intensive fludarabine and cytarabine schedule in older patients with untreated acute myeloid leukemia.
Vives S; Martínez-Cuadrón D; Bergua Burgues J; Algarra L; Tormo M; Martínez-Sánchez MP; Serrano J; Herrera P; Ramos F; Salamero O; Lavilla E; López-Lorenzo JL; Gil C; Vidriales B; Falantes JF; Serrano A; Labrador J; Sayas MJ; Foncillas MÁ; Amador Barciela ML; Olave MT; Colorado M; Gascón A; Fernández MÁ; Simiele A; Pérez-Encinas MM; Rodríguez-Veiga R; García O; Martínez-López J; Barragán E; Paiva B; Sanz MÁ; Montesinos P;
Cancer; 2021 Jun; 127(12):2003-2014. PubMed ID: 33626197
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
